SAN DIEGO, Oct. 11, 2017 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of cancer patients, announces
that Fred R. Hirsch, M.D., Ph.D. has
joined its Clinical Advisory Board. Dr. Hirsch is Professor
of Medicine and Pathology at the University of
Colorado Cancer Center.
"I am excited to join Biocept as a clinical advisor as the
Company develops and expands its liquid biopsy offering," said Dr.
Hirsch. "The ability to rapidly and non-invasively determine
actionable biomarkers present in a patient's tumor can optimize
personalized treatment. Biocept's use of highly sensitive
assays for both circulating tumor cells (CTCs) and circulating
tumor DNA (ctDNA) to accomplish this is a novel approach that holds
promise for improving cancer profiling and treatment."
"We welcome Dr. Hirsch to our Clinical Advisory Board and look
forward to benefitting from his significant expertise in lung
cancer," said Biocept's President and Chief Executive Officer
Michael Nall. "Dr. Hirsch is a
prominent figure in the clinical and academic communities focused
on lung cancer, and has received numerous awards and authored
hundreds of peer-reviewed papers. He is involved in studies
of lung cancer diagnosis, staging, prevention, early detection and
treatment that have favorably impacted the care of lung cancer
patients, and his research has helped to identify and validate
predictive markers for personalized lung cancer therapies.
"We are extremely proud of our ability to attract the leading
advisors assembled on our Clinical Advisory Board in order to
support our objective of improving the outcomes of patients with
cancer," added Nall. "This group is playing an important
advisory role in helping us understand how our tests are being used
in a clinical setting and on other aspects of our business, as
liquid biopsy moves toward standard of care."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company leverages its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. Biocept's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are
based upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
be correct. Forward-looking statements are generally identifiable
by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend" or
"project," or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this news release are not strictly historical,
including, without limitation, statements as to our ability to
identify specific clinical conditions or improve the outcomes of
cancer patients, the utility and effectiveness of our intellectual
property protections, the financial impact of new contracts
including the retention of services of certain physicians or other
individuals, and our ability to increase the number of products or
services provided or the value of the Company, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this news release. We
do not plan to update any such forward-looking statements and
expressly disclaim any duty to update the information contained in
this press release except as required by law. Readers are advised
to review our filings with the SEC at www.sec.gov
View original content with
multimedia:http://www.prnewswire.com/news-releases/renowned-lung-cancer-expert-fred-r-hirsch-md-phd-joins-biocepts-clinical-advisory-board-300534551.html
SOURCE Biocept, Inc.